Under COVID of the night

Sekeres, Mikkael A.

doi:10.1182/blood.2020009377

Cited by 1 publication

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, we could draw conclusions on a population with a wide age distribution, affected by lymphoid malignancies with variable disease status, and with several lymphoma histologies that were well represented. With the present study, we can conclusively say that fatality rate of hospitalized patients with lymphoma is high (33.4%), which was in line with smaller retrospective series from the literature on lymphoma patients 17,23 , or on HM in general [12][13][14][15][16]24 . Furthermore, we could establish for the first time the relatively low mortality rate (3.8%) of patients that were managed as outpatients.…”

Section: Discussionsupporting

confidence: 90%

“…We observed no differences in survival for patients on active anti-lymphoma treatment (≤6 months), as compared to all others (Table 2). This observation confirms other observations on lymphoma patients 14,17,23 , but differs from what generally reported in solid cancer patients, where active treatment has been associated with increased risk of death 29,30 , although not uniformly 13,31 . Anti-CD20 containing therapy, as already observed by others 16 , did not impact the short-term outcome, as was the case of the number of previous anti-lymphoma lines of therapy.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

et al. 2022

View full text Add to dashboard Cite

Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behaviour and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not admitted cohort, n=388), or required hospitalization (n=468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95%CI 11-15%) and 23% (95%CI 20-27%), respectively. Anti-lymphoma treatment, including anti-CD20 containing regimens, did not impact on survival. Patients with Hodgkin's lymphoma had the more favourable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment for their underlying disease, and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.

show abstract